- Johnson & Johnson pauses Varipulse heart device rollout in the U.S. due to reported stroke events.
- Varipulse received FDA approval in November for treating abnormal heart rhythm.
- The pause is part of an investigation, with no impact outside the U.S.
- J&J aims to resume the U.S. external evaluation.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
